BACKGROUND: Despite several clinical trials and advances in understanding the genetic basis of biliary tract cancer (BTC), the addition of epidermal growth factor receptor (EGFR) targeted therapy does not seem to enhance the activity of first-line chemotherapy (CHT). MATERIALS AND METHODS: We carried out a meta-analysis of available randomized clinical trials to assess the efficacy and safety of gemcitabine-based first-line CHT plus monoclonal antibodies against EGFR (EGFR-mAbs) in advanced or metastatic BTC. RESULTS: In the overall population, the pooled hazard ratio for overall (OS) and progression-free (PFS) survival were 0.82 (95% confidence interval=0.64-1.06) and 0.88 (95% confidence intervaI=0.73-1.08), respectively. No differences were detected in objective response rate between the two groups. Patients treated with gemcitabine-based CHT plus EGFR-mAbs showed a statistically significant increased risk of grade 3-4 neutropenia, grade 3-4 thrombocytopenia and especially grade 3-4 skin rash. CONCLUSION: The addition of EGFR-mAbs to gemcitabine-based first-line CHT does not significantly improve overall and progression-free survival, nor the objective response rate in patients with advanced BTC and increases the risk of hematological and cutaneous adverse drug events. Copyright
BACKGROUND: Despite several clinical trials and advances in understanding the genetic basis of biliary tract cancer (BTC), the addition of epidermal growth factor receptor (EGFR) targeted therapy does not seem to enhance the activity of first-line chemotherapy (CHT). MATERIALS AND METHODS: We carried out a meta-analysis of available randomized clinical trials to assess the efficacy and safety of gemcitabine-based first-line CHT plus monoclonal antibodies against EGFR (EGFR-mAbs) in advanced or metastatic BTC. RESULTS: In the overall population, the pooled hazard ratio for overall (OS) and progression-free (PFS) survival were 0.82 (95% confidence interval=0.64-1.06) and 0.88 (95% confidence intervaI=0.73-1.08), respectively. No differences were detected in objective response rate between the two groups. Patients treated with gemcitabine-based CHT plus EGFR-mAbs showed a statistically significant increased risk of grade 3-4 neutropenia, grade 3-4 thrombocytopenia and especially grade 3-4 skin rash. CONCLUSION: The addition of EGFR-mAbs to gemcitabine-based first-line CHT does not significantly improve overall and progression-free survival, nor the objective response rate in patients with advanced BTC and increases the risk of hematological and cutaneous adverse drug events. Copyright
Authors: Alessandro Rizzo; Angela Dalia Ricci; Giorgio Frega; Andrea Palloni; Stefania DE Lorenzo; Francesca Abbati; Veronica Mollica; Simona Tavolari; Mariacristina DI Marco; Giovanni Brandi Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155
Authors: Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich Journal: Cancers (Basel) Date: 2022-06-11 Impact factor: 6.575
Authors: Angela Dalia Ricci; Alessandro Rizzo; Chiara Bonucci; Simona Tavolari; Andrea Palloni; Giorgio Frega; Veronica Mollica; Nastassja Tober; Elena Mazzotta; Cristina Felicani; Carla Serra; Giovanni Brandi Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Jose J G Marin; Paula Sanchon-Sanchez; Candela Cives-Losada; Sofía Del Carmen; Jesús M González-Santiago; Maria J Monte; Rocio I R Macias Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639